---
run_id: halo-evidence-vs-diagnosis-validation-v9-substrate-workflow-08
created: 2026-05-24
eval_type: contradiction-preservation
case_id: halo-evidence-vs-diagnosis-validation-v9
benchmark_version: halo-evidence-vs-diagnosis-validation-v9-v1
model_condition: substrate_workflow
run_number: 8
model_name: gemma-4-31b-it-mlx
model_id: gemma-4-31b-it-mlx
model_snapshot: LM Studio MLX 8-bit model id lmstudio-community/gemma-4-31B-it-MLX-8bit
runtime: LM Studio local OpenAI-compatible HTTP server; MLX runtime
provider: local
temperature: 0.7
top_p: 0.9
num_ctx: 32768
max_tokens: 1024
seed: 803
prompt_source: condition packet (substrate_workflow) - frozen added material plus frozen Advisor prompt; see run-packet.md
prompt_sha256: 61d771e2bff7fd2e18be1d2999d0f601760656e3e69b4622989ca7bffd3aff8e
source_packet: a substrate preamble plus three reviewed source cards, then the frozen Advisor prompt - see run-packet.md
source_packet_sha256: 8c1fbdb9b2af9238d4533dece4ffc185fda2e1f7ecb6008913243d23d9a67c63
condition_packet_sha256: 8c1fbdb9b2af9238d4533dece4ffc185fda2e1f7ecb6008913243d23d9a67c63
output_file: model-outputs/substrate_workflow-08.md
judge_model_id: pending - judge receipts recorded separately under judge-packet
judge_prompt_sha256: pending - judge receipts recorded separately under judge-packet
judge_independence: pending - judge receipts recorded separately under judge-packet
raw_model_output_public_safe: true
---

# Model Output - substrate_workflow (run 08)

## Condition

Benchmark version `halo-evidence-vs-diagnosis-validation-v9-v1`, condition `substrate_workflow`, run 8 of 8. Real local-model run: `gemma-4-31b-it-mlx` via lmstudio, seed 803, on the frozen condition packet.

## Output

I recommend that you commit to the **Claim File Review**.

### Reasoning
The current evidence is "entangled" by several distorting factors described in your artifacts:

1.  **Performance-Aware Attribution (BK-0048):** The executive team’s current praise—calling the product team "focused" and "disciplined"—is likely contaminated by the strong quarterly results (expansion bookings). This is a trait narrative triggered by an outcome, not independent evidence of strategic alignment.
2.  **False Progress Metrics (BK-0007):** The 39% usage increase is a "broad activity metric" that masks the reality. High frequency is driven by managers (not users) and initial rollout spikes, while front-line adjusters are reverting to manual notes. The "reduction" in support tickets is a reporting artifact (shifting to training channels), not an improvement in product quality.
3.  **Lack of Load-Bearing Diagnosis (BK-0001):** You do not yet know if the "problem" being solved is a lack of feature capability, a failure in user enablement, or a fundamental compliance gap (as seen in the health-liability segment).

The **Claim File Review** is the only option that provides a "load-bearing diagnosis." By inspecting actual claim files, you move past persuasive stories and activity dashboards to see if the product is actually solving the core challenge. It tests the critical uncertainty: *Is DraftPath providing value that adjusters trust and can defend, or is it a superficial tool being pushed by sales bundles?*

The other options are insufficient: the *Usage Quality Sprint* relies on the same activity metrics that are already misleading; the *Commercial Cleanroom* tests sales tactics rather than product value; and *scaling broadly* risks baking in a failure that is currently hidden by bundle pricing.

### The Strongest Reason Against This Recommendation
The Claim File Review is a qualitative, small-sample approach that will not provide the "hard" statistical confidence some board members crave. It is slower to execute than a dashboard sprint and may uncover "ugly" truths (e.g., that the product is fundamentally unusable in regulated segments) just as the budget is being locked, potentially creating friction with a leadership team currently riding a "high" from the quarterly results.

### Evidence That Would Change My Mind
I would change this recommendation to **"Narrow the company plan around regulated health-liability workflows"** if the Claim File Review reveals that the "impossible to explain" barrier is not a training issue, but a legal/regulatory requirement for auditability that DraftPath cannot currently meet. If the product is fundamentally incompatible with the highest-value, most regulated segment, scaling it broadly—even if "usable" in simpler segments—would be a strategic error.
